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Mutations in the MAPT gene can lead to disease-associated variants of tau. However,
the pathological mechanisms behind these genetic tauopathies are poorly understood.
Here, we characterized the aggregation stages and conformational changes of tau
C291R, a recently described MAPT mutation with potential pathogenic functions. The
C291R variant of the tau four-repeat domain (tau-K18; a functional fragment with
increased aggregation propensity compared with the full-length protein), aggregated into
a mix of granular oligomers, amorphous and annular pore-like aggregates, in native-
state and heparin-treated reactions as observed using atomic force microscopy (AFM)
and negative-stained electron microscopy. On extended incubation in the native-state,
tau-K18 C291R oligomers, unlike wild type (WT) tau-K18, aggregated to form protofibrils
of four different phenotypes: (1) spherical annular; (2) spherical annular encapsulating
granular oligomers; (3) ring-like annular but non-spherical; and (4) linear protofibrils.
The ring-like tau-K18 C291R aggregates shared key properties of annular protofibrils
previously described for other amyloidogenic proteins, in addition to two unique
features: irregular/non-spherical-shaped annular protofibrils, and spherical protofibrils
encapsulating granular oligomers. Tau-K18 C291R monomers had a circular dichroism
(CD) peak at ∼210 nm compared with ∼199 nm for tau-K18 WT. These data suggest
mutation-enhanced β-sheet propensity. Together, we describe the characterization
of tau-K18 C291R, the first genetic mutation substituting a cysteine residue. The
aggregation mechanism of tau-K18 C291R appears to involve β-sheet-rich granular
oligomers which rearrange to form unique protofibrillar structures.
Keywords: MAPT mutations, tau C291R, corticobasal degeneration, granular oligomer, annular protofibril, linear
protofibril, atomic force microscopy, transmission electron microscopy
INTRODUCTION
Tau protein is a product of the microtubule-associated protein tau (MAPT) gene located on
chromosome 17q21 (Neve et al., 1986; Andreadis et al., 1992). MAPT is comprised of 16 exons,
producing six tau isoforms in the adult human brain (Goedert et al., 1988, 1989). Tau has two
significant components: the N-terminus projection domain and the assembly domain covering
Abbreviations: AFM, atomic force microscopy; CBD, corticobasal degeneration; CD, circular dichroism; C291A, cysteine-291
substituted with alanine; C291R, cysteine-291 substituted for arginine; C291S, cysteine-291 substituted for serine; MTBR,
microtubule-binding region; NaPhos, sodium phosphate; TBS-T, Tris-buffered saline plus Tween; TEM, transmission
electron microscopy; WT, wild type.
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the microtubule-binding region (MTBR) and the C-terminus
region (Andreadis et al., 1992; Andreadis, 2005). Variations
in the number of N-terminus domains (0, 1 or 2) and
MTBR domains (3 or 4 repeats) are the defining features of
different isoforms (Andreadis et al., 1992; Andreadis, 2005).
Notably, alternative splicing of exon 10 affects the ratio of
three- to four-repeat tau isoforms, changes in which have
been linked to several tauopathies (Liu and Gong, 2008).
Indeed, many MAPT mutations located in or around exon
10 have been reported from individuals affected by different
genetic tauopathies, with over a dozen implicated in disease
(Goedert and Jakes, 2005; Ghetti et al., 2015). However, until
recently, none of the described mutations affected a cysteine
residue. Each tau isoform has either one or two cysteine
residues, depending on the number of repeat domains in
the MTBR: four-repeat isoforms have two cysteine residues,
at positions 291 and 322, whilst three-repeat isoforms have
only cysteine-322. Therefore, cysteine-322 is ubiquitous to
all tau isoforms whilst cysteine-291 is limited to four-repeat
isoforms. Several studies have reported that the presence of
the cysteine-291 residue is important for tau aggregation and
that the cysteine-322 residue may be inhibitory to this process
(Bhattacharya et al., 2001; Crowe et al., 2013; Soeda et al., 2015;
Al-Hilaly et al., 2017).
In 2015, Marshall et al. (2015) identified a cysteine-modifying
MAPT mutation altering cysteine-291 to arginine in a patient
diagnosed with corticobasal degeneration (CBD) with apraxia
of speech. This residue is sandwiched between two XSK
tripeptide motifs (where X = Q or G; Figure 1), changing
it to arginine (Marshall et al., 2015). The disease relevance
of this potential genetic form of CBD as yet cannot be
confirmed since it has neither been observed at post-mortem
nor traced to any relative of the patient. However, given
the importance of cysteine residues, particularly cysteine-
291, to specific physiological and pathophysiological functions
of tau, including acetyltransferase activity and aggregation
(Schweers et al., 1995; Cohen et al., 2013; Soeda et al.,
2015; Al-Hilaly et al., 2017; Chen et al., 2018), we were
interested in understanding how the C291R mutation might
affect tau aggregation. Importantly, the core of tau filaments
isolated from CBD patient brains consist of a broad range of
amino acids (amino acids 274–380 of full-length tau) covering
cysteine-291 and the lysine residues that immediately surround
it (Zhang et al., 2020). These lysine residues immediately
flanking cysteine-291 on either side (lysine-290 and lysine-
294) are thought to strengthen cysteine-291’s disulfide bonding
capacity, a property critical to tau protein’s aggregation both
in vitro and in vivo (Cisek et al., 2014). Indeed, the side
chains of lysine-290 and lysine-294 are key components of
an extra density structure within CBD filament folds (Zhang
et al., 2020). We, therefore, hypothesized that substituting the
hydrophobic cysteine-291 residue with arginine will generate a
new stretch of basic amino acids that might lead to functional
consequences on aggregation and conformation. In this study,
we present the first biochemical characterization of tau C291R
focusing on its step-wise aggregation stages, conformational and
structural changes.
MATERIALS AND METHODS
Cloning, Protein Expression and
Purification
We generated the pProEx-HTa-Myc-6 × His-K18 plasmid
carrying the C291R mutation (TGT > CGT, the same codon
change previously reported by Marshall et al., 2015) by
site-directed mutagenesis using a WT tau-K18 plasmid as a
template (Karikari et al., 2017, 2019a). Protein expression and
purification were achieved using our previously-characterized
recombinant tau production protocols (Karikari et al., 2017,
2019a,b; Hill et al., 2019). The purified His-tagged tau-K18
constructs were used directly in functional experiments since
the His-tag does not appear to affect aggregation (Huseby
et al., 2019). Protein concentration was estimated using a
Bicinchoninic acid assay kit from G-Biosciences (#786–570).
Circular Dichroism (CD) Spectroscopy
A Jasco J-815 CD spectropolarimeter was used to collect CD
spectra on 22 µg/ml of purified tau-K18 WT and tau-K18
C291R, each diluted in 10 mM sodium phosphate (NaPhos)
buffer pH 7.4. The following conditions were used: cell path
length = 1 mm, data pitch = 0.1 nm, response time = 1 s,
wavelength range = 190 nm – 240 nm, scan speed = 100 nm/min,
and high-tension voltage = ≤550 V. Averages of 10 spectral
accumulations were analyzed.
Heparin-Induced Aggregation Analysis
A 2:1 mass concentration ratio reaction mix of WT or C291R
tau-K18 to heparin was prepared using 0.8 mg/ml of tau-K18 and
0.4 mg/ml of heparin in a total volume of 20 µl. The mixture
was incubated at 37◦C without shaking for 48 h to form fibrils.
Five microliters of each sample were spotted on Formvar carbon-
coated 300-mesh copper grids (#AGS162-6, Agar Scientific,
Stansted, UK) and allowed 2 min to bind. The unbound sample
was removed by blotting with filter paper and 5 µl of uranyl
acetate added for 2 min. A JEOL JEM-2010 transmission electron
microscope (TEM) was used to image the samples.
Native-State Aggregation Time Course
The tau-K18 preparations were incubated in 10 mM NaPhos
buffer pH 7.4 at 37◦C for 0, 24, 72, 168, 216 and 314 h. At each
time point 10 µl aliquots were removed, snap-frozen and stored
at −80◦C until further analysis by atomic force microscopy
(AFM) as described below.
AFM Analysis of Aggregation Stages
Tau-K18 samples (0.5 mg/ml) from the aggregation time course
experiment were spotted on to freshly-cleaved 11 mm × 11 mm
mica sheets (#AGG250-3, Agar Scientific, Stansted, UK). Once
dried, the unbound protein was washed away with sterile water
and the mica sheet air-dried and analyzed in AC Air Topography
(tapping) mode on an Asylum Research MFP3D-SA instrument.
A scan size of 20 µm, a scan rate of 1 Hz, set point of 590.49 mV,
an integral gain of 3, x- and y- offsets of 0, points and gains of
256 and drive amplitude of 129.06 mV were used. The Igor Pro
6.37 image processing and programming software was used for
image processing.
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FIGURE 1 | Schematic illustration of the tau-K18 C291R construct used in this study. The microtubule-binding region of tau (amino acids 244–372 of full-length
tau-441; also known as tau-K18) was cloned into a pProEx-HTa plasmid and the C291R mutation introduced by site-directed mutagenesis and sequence-verified.
This genetic construct was transformed into BL21(DE3)*pRosetta Escherichia coli, expressed and purified following a previously-described protocol also used for
preparing wild type tau-K18 (Karikari et al., 2017).
FIGURE 2 | Circular dichroism (CD) profiles of tau-K18 WT (A) and C291R (B) monomers. Each construct was diluted in 10 mM NaPhos buffer pH 7.4 at 22 µg/ml
final protein concentration and the secondary structure profiles analyzed as described in the “Materials and Methods” section.
RESULTS
Secondary Structure Profile of Tau-K18
C291R
Tau-K18 is generally unfolded but adopts β-sheet conformation
with increasing aggregation (Kumar et al., 2014; Karikari et al.,
2017). Specific MAPT mutations have distinct effects on this
process by either increasing or decreasing the propensity to form
β-sheet structures (Barghorn et al., 2000; Combs and Gamblin,
2012; Karikari et al., 2019a). To understand the possible effects
of the C291R mutation on β-sheet formation, the secondary
structure content of monomeric tau-K18 C291R and the WT
were studied with CD spectroscopy. The experimental data
in millidegrees were reconstructed in the Dichroweb database
and the expected data (reconstructed minus experimental data)
plotted in Figure 2. WT tau-K18 had a minimum peak of
∼199 nm whilst tau-K18 C291R had a peak at ∼210 nm
(Figures 2A,B respectively), suggesting that the C291R variant
has a higher propensity to adopt β-sheet conformation.
Tau-K18 C291R Aggregates Into
Amorphous and Spherical Structures, but
Not Fibrils, Over 48 h in the Presence of
Heparin
As cysteine-291 is important for tau aggregation (Bhattacharya
et al., 2001; Crowe et al., 2013; Soeda et al., 2015), we asked
if the C291R mutation affects aggregation propensity. Each
tau-K18 construct was mixed with a 50% mass concentration
of heparin and incubated at 37◦C without shaking for
48 h. Negative-stain TEM analysis showed that tau-K18 WT
aggregated into fibrils (Figure 3A) in agreement with previous
reports (Barghorn et al., 2000; Barghorn and Mandelkow,
2002; Karikari et al., 2017). These fibrils were 30–45 nm
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FIGURE 3 | Negative-stain transmission electron microscope (TEM)
micrographs of aggregates of tau-K18 WT (A) and C291R (B) formed after
treating 0.8 mg/ml of each construct with 0.4 mg/ml of heparin and
incubating for 48 h at 37◦C without shaking. Panel (A) shows fibrils with the
inset highlighting the periodic twists of ∼50 nm (white arrowheads). Panel (B)
shows amorphous aggregates, with the inset showing annular aggregates
with defined outer structures (arrowheads). Scale bars = 50 nm for both main
figures and insets.
wide and 150–300 nm long. On the contrary, tau-K18 C291R
mostly formed amorphous structures without any regular
shape or form (Figure 3B) in addition to annular aggregates
20–50 nm wide (Figure 3B, inset). These results suggest that
the C291R mutation averts tau-K18 aggregation into fibrils,
but rather favors the formation of non-fibrillar oligomers and
amorphous assemblies.
Tau-K18 C291R Aggregates Into
Non-fibrillar Amorphous and Annular
Structures in Native-State Conditions
To exclude the possibility that tau-K18 C291R’s aggregation into
non-fibrillar structures was dependent on heparin induction, the
experiment was repeated in native-state conditions by incubating
both tau constructs in identical conditions as in Figure 3 except
that no heparin was added. Aggregation was slower in this
condition as anticipated (Karikari et al., 2019a). However, this
approach allowed the fine mechanistic details of the process to
be studied. AFM imaging revealed that tau-K18 WT monomers
(Figure 4Ai) aggregated into granular oligomers (Figure 4Aii)
and protofibril-like structures after 24 h (Figure 4Aii, inset).
Clusters of aggregates identified at this stage (Figure 4Aii, white-
filled arrowheads) were likely to be off-pathway structures that
did not follow amyloidogenic aggregation. More filamentous
structures (protofibrils and short fibrils) were observed at 72 h
through 216 h (Figures 4Aiii–v, black arrowheads). Bonafide
fibrils of up to 7 µm in length with paired helical filament (PHF)
structure were recorded at 314 h (Figure 4Avi). This data shows
that under careful conditions, tau-K18 WT can self-assemble
into Alzheimer-like PHFs without the need for any external
activation. Similar heparin-free aggregation studies have been
performed for the recombinant form of a tau peptide (amino acid
297–391) that is a major component of PHF tau isolated from
Alzheimer’s disease brains (Al-Hilaly et al., 2017, 2018, 2019).
For tau-K18 C291R, small-sized structures at 0 h (Figure 4Bi)
shifted towards more granular orientation with increased sizes
(5–10 nm) at 24 h, with large amorphous structures over 3 µm
also evident at this stage (Figure 4Bii, inset). This coexistence
of oligomers and amorphous aggregates was also observed at
72 h rather with increased oligomer sizes (Figure 4Biii). At
168 h, several medium-sized amorphous structures ∼1 µm
became evident (Figure 4Biv, arrowheads). Closer inspection
showed that these amorphous structures contained granular
oligomers (Figure 5A, arrowheads), suggesting that some
oligomers were either absorbed into the amorphous structures
or the oligomers rearranged to form these large structures.
Regular granular oligomers were also visible (Figure 5A,
arrows), signifying the coexistence of two distinct types of
aggregates i.e., granular oligomers and amorphous structures.
At 216 h, granular oligomers became less prominent but the
medium-sized amorphous structures prevailed (Figure 4Bv).
In addition, new structures with well-defined traces were
recorded, which at higher resolution were made of various-sized
amorphous clumps and groups of granular oligomers apparently
in the process of forming amorphous clumps (Figure 5B,
black arrowheads and arrows, respectively). Moreover, small
ring-like annular structures made of granular oligomers were
recorded beginning to take shape at 216 h (Figure 5B, white
arrows). By 314 h, larger ring-like structures including those
enclosing granular oligomers were observed (Figures 4Bvi,
5C inset). The structures with well-defined traces formed at
late time points were similar to the amorphous aggregates
imaged in negative-stained conditions in Figure 3B. Together,
these results indicate that the C291R mutation leads to
drastic changes in the aggregation pathway and products
of tau-K18, suggesting an altered conformational effect of
the mutation.
Tau-K18 C291R Forms Different Types of
Protofibrils
We characterized the C291R annular protofibrils formed at 314 h
binning into four phenotypes, namely:
1. Spherical protofibrils: protofibrils consisting of granular
oligomers arranged in a spherical manner. The sizes
(diameter) of these aggregates ranged from 50 to 100 nm, as
well as up to over 1,000 nm (Figure 6A).
2. Spherical annular protofibrils encapsulating granular
oligomers: in addition to being made of granular oligomers
arranged in a spherical, ring-like structure, these aggregates
consisted of single granular oligomer units dispersed within
the enclosed structure (Figure 6B). These annular protofibrils
were less frequently observed compared to the spherical
ones above.
3. Ring-like annular but non-spherical protofibrils: These
aggregates consisted of granular oligomers arranged in a
non-spherical (often undefined) orientation (Figure 6C). The
main similarity between this and the spherical protofibrils
(phenotypes 1 and 2) is that they always formed a close-loop.
4. Linear protofibrils: these consisted of linearly arranged
granular oligomers (Figure 6D), and differed from the other
types of protofibrils by their arrangement compared to the
ring-like structures of the others.
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FIGURE 4 | Atomic force microscopy (AFM) images of tau-K18 WT (A) and C291R (B) aggregates formed over 314 h in native state conditions (incubation at 37◦C
without shaking). WT tau-K18 aggregated into fibrils at 314 h (arrowhead) via granular oligomers and protofibrils intermediates recorded at earlier time points. The
C291R variant initially aggregated into granular oligomers, amorphous aggregates and later into different types of protofibrils. Scale bars = 1 µm for all images.
Further details about the intermediate structures may be found in the “Results” section.
FIGURE 5 | Increased resolution AFM images of tau-K18 C291R at later stages of the native-state aggregation process. Aggregate structures formed at 168 h (A),
216 h (B) and 314 h (C) show granular oligomers (black arrows), amorphous aggregates (black arrowheads) and annular protofibrils including those encapsulating
granular oligomers (inset in C). Scale bars = 1 µm.
The frequency distribution of the protofibrils at 314 h, based
on structure counts from AFM images from three experiments,
can be found in Table 1.
DISCUSSION
In vitro biochemical studies provide critical molecular insights
into potential disease-causing mechanisms of MAPT mutations
identified in humans affected by specific tauopathies including
effects on tau aggregation, phosphorylation, and microtubule-
binding (Ghetti et al., 2015; Strang et al., 2019). However, little is
known aboutMAPT mutations discovered more recently. In this
study, we have provided the first biochemical characterization of
the C291R tau variant, reported to have potentially pathogenic
functions (Marshall et al., 2015). Cysteine-291 is a core
component of CBD tau filament structure (Zhang et al.,
2020), hence mutagenic changes are likely to have potential
effects on aggregation properties. Our results demonstrate
that the C291R mutation leads to a striking distinction in
the aggregation mechanism of tau-K18 compared with the
WT. Whilst WT tau-K18 underwent classical aggregation by
progressively forming granular oligomers, protofibrils and fibrils,
the C291R variant formed a mix of aggregates of three
different major types: (1) granular oligomers, (2) amorphous
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FIGURE 6 | Tau-K18 C291R forms linear and annular protofibrils of distinct phenotypes. (A) Classical spherical annular protofibrils, (B) spherical annular protofibrils
encapsulating dispersed granular oligomers, (C) annular aggregates of undefined shape, and (D) classical linear protofibrils. Scale bars = 1 µm.
TABLE 1 | Frequency distribution of protofibrils phenotypes for tau-K18 C291R.
Phenotype Frequency (n, %)
Spherical 223/329 (67.8%)
Linear 56/329 (17.0%)
Ring-like annular but non-spherical 42/329 (12.8%)
Spherical encapsulating oligomers 8/329 (2.4%)
aggregates of various sizes and shapes, and (3) protofibrils—both
linear and annular structures made of granular oligomers.
It is noteworthy that these observations were made in both
heparin-induced and native state aggregation reactions and
imaged using two different methods—negative-stained TEM and
label-free AFM. Importantly, we did not record obvious fibrillar
aggregates for tau-K18 C291R but observed that in addition
to regular linear protofibrils, this variant formed annular
aggregates with unique features. Together, these lines of evidence
are consistent with our hypothesis that the C291R mutation
results in an altered aggregation pathway with aggregate
conformers of distinct structural properties compared with WT
tau-K18 aggregates.
The aggregation of tau-K18 C291R into a mix of granular
oligomers, annular structures, and amorphous aggregates
appears to be an off-pathway process with respect to fibril
formation (Ding et al., 2002; Lasagna-Reeves et al., 2014).
Key properties of this non-fibrillar pathway were clearly
identified from our AFM analysis: the process begun with the
formation of granular oligomers, which further polymerized
into amorphous aggregates of various sizes and, at later time
points, annular structures. The annular aggregates were made of
granular oligomers arranged in a ring-like shape with defined
outer structures. These properties easily differentiated them
from the amorphous structures (see Figures 4B, 5C) and
regular granular oligomers (Kayed et al., 2009). Due to their
defined multi-oligomer presentation, annular aggregates are
often referred to as annular protofibrils, pore-like structures or
pore-forming aggregates, and have been widely characterized
for amyloid-beta and alpha-synuclein (Ding et al., 2002; Lashuel
et al., 2002; Kayed et al., 2009), and in a single report
for tau (Lasagna-Reeves et al., 2014). In the case of tau,
annular aggregates were identified, using TEM, AFM, and
a conformation-specific antibody, in post mortem brains of
dementia with Lewy body and progressive supranuclear palsy
patients. Moreover, annular aggregates were reported from
brain isolates of P301L tau-expressing mice, but not WT
mice, suggesting an association with specific MAPT mutations
(Lasagna-Reeves et al., 2014).
In the present study, we have demonstrated that a new,
potentially pathogenic variant of tau, C291R, also forms annular
aggregates in vitro in addition to linear protofibrils. Importantly,
the annular aggregates shared the following striking similarities
with those described previously for tau, amyloid-beta, and alpha-
synuclein: (1) their formationwas preceded by spherical/granular
oligomers; (2) the annular aggregates consisted of granular
oligomers often arranged in a spherical fashion; (3) spherical
annular aggregates were in a range of sizes; (4) annular
aggregates were associated with a specific pathogenic mutation;
and (5) pore-like annular protofibrils were clearly distinguishable
from linear protofibrils which usually proceed to form fibrils
(Ding et al., 2002; Lashuel et al., 2002, 2003; Lasagna-Reeves
et al., 2014). In addition, two unique phenotypes of the
tau-K18 C291R annular aggregates previously not described for
an amyloidogenic protein/peptide were characterized, namely:
(1) the spherically arranged granular oligomers that formed
the annular aggregates occasionally enclosed small, single-unit
granular oligomers within their larger ring structures (Figure 5C
inset and Figure 6B); and (2) the ring-like shape of annular
aggregates did not always have a spherical appearance. In fact, the
shape was sometimes irregular and undefined (Figures 4Bv,vi,
5C, 6C). Together, we have demonstrated that the ring-like
tau-K18 C291R aggregates possess key properties of annular
protofibrils previously described for other amyloidogenic
proteins. The new phenotypes presented to warrant further
characterization in future studies.
Previous reports showed that substituting cysteine-291 with
alanine (C291A) in WT tau forms affects the aggregation
propensity, showing this reduces oligomer formation (Kim
et al., 2015; Soeda et al., 2015; Al-Hilaly et al., 2017),
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demonstrating also that this does not prevent fibril formation
(Barghorn and Mandelkow, 2002; Furukawa et al., 2011).
Similarly, modifying cysteine-291 to serine (C291S) reduced its
oligomerization competence (Kim et al., 2015). Together, these
studies suggested that substituting cysteine-291 with Ala or Ser
(both aliphatic amino acids) have similar effects. Moreover, we
and others have shown that the C291A/C322A/I260C triple-
modified K18 variant aggregates into both oligomers and
fibrils (Kumar et al., 2014; Michel et al., 2014; Shammas
et al., 2015; Karikari et al., 2019a,b). However, none of these
modifications led to the formation of annular aggregates.
Curiously, the C291A and C291S mutations both decreased
aggregation competence in a manner distinct from the
current C291R with a polar amino acid introduced, suggesting
the choice of amino acid makes an important difference.
Notably, the introduction of arginine at cysteine-291 had
adverse effects on fibrillization processes but not oligomer
formation as the C291R construct readily formed oligomers.
We propose that the C291R mutation selectively impairs the
conformational changes leading from oligomers to fibrils but
not from monomers to oligomers. Cysteine residues in tau
are surrounded by lysine residues whose basic charges enable
disulfide bonding which is critical for aggregation (Lutolf
et al., 2001). Removing one of the two cysteine residues in
tau-K18 weakens its inter-molecular disulfide binding and hence
aggregation tendency. The veracity of these hypothetical models
need to be tested experimentally.
Although tau-K18 C291R did not form bona fide fibrils in the
present study, we cannot rule out that the same construct can
form fibrils under different experimental conditions (e.g., using
different buffers and aggregation-inducing agents). Similar to our
findings that linear and annular protofibrils of tau C291R were
jointly present in the same reaction (see Figure 6), annular and
fibrillar alpha-synuclein aggregates have been shown to co-exist
in the same conditions (Shtilerman et al., 2002). Furthermore, tau
P301L can form fibrils as well as annular aggregates in vitro and
in vivo (Lasagna-Reeves et al., 2014), suggesting a high potential
for co-existence.
A limitation of this study is that the proposed pathogenicity
of the C291R mutation has not been confirmed by
neuropathological examination. Therefore, the mutation
and its functional properties described in this manuscript
cannot be presently linked to CBD or any other form of
tauopathy. Nonetheless, the results provide insights into the
functional and structural properties of this novel mutation and
sheds new light on the biochemical basis of tau aggregation.
Moreover, reported differences in aggregate structures of human
brain-derived tau and recombinant tau aggregated in vitro
by inducing with heparin (Zhang et al., 2019) may limit the
utility of the findings presented in this study. However, a more
recent study showed close similarities between brain-derived tau
filaments and those formed by the amino acid 297–391 fragment
self-assembled in vitro without any external inducing agents
(Al-Hilaly et al., 2019). Given that the tau-K18 C291R construct
studied herein could also self-aggregate and contains about
half of the tau 297–391 sequence, the findings of this study
are likely to have potential implications for future in vivo and
neuropathological studies.
CONCLUSION
We have presented the first biochemical characterization of tau
C291R, covering its secondary structure, step-wise aggregation
stages, and conformational properties. A novel, significant
finding is that tau C291R forms annular, pore-like aggregates,
the second time this phenomenon has been described for a
tau construct after tau P301L. Importantly, the C291R annular
aggregates share major properties described for such structures
formed by amyloid-beta, alpha-synuclein and tau P301L but also
has two unique features previously unknown: (1) spherically
arranged granular oligomers that enclose small, single-unit
granular oligomers; and (2) non-spherical ring-like annular
aggregates. These findings, and their further characterization
in future studies, should pave the way for further studies
into the C291R tau variant and how the annular aggregates it
forms could provide new insights into the aggregation process
of tau.
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